US · CPIX
Cumberland Pharmaceuticals Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Nashville, TN 37203
- Website
- cumberlandpharma.com
Price · as of 2024-12-31
$4.36
Market cap 73.59M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $125.07 | +2,768.58% |
| Intrinsic Value(DCF) | $3.00 | -31.19% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.16 | $41.15 | $10.04 | $4.43 | $1.61 |
| 2011 | $7.73 | $4,093.97 | $9.91 | $4,812.99 | $5.29 |
| 2012 | $4.63 | $38.78 | $3.67 | $5.87 | $1.17 |
| 2013 | $4.75 | $91.61 | $2.93 | $3.76 | $2.84 |
| 2014 | $6.78 | $59.65 | $3.60 | $5.27 | $3.12 |
| 2015 | $4.59 | $40.31 | $3.37 | $4.82 | $0.00 |
| 2016 | $6.20 | $121.56 | $3.53 | $4.35 | $0.00 |
| 2017 | $6.79 | $195.68 | $3.09 | $1.52 | $0.00 |
| 2018 | $5.80 | $631.94 | $2.19 | $1.30 | $0.00 |
| 2019 | $4.18 | $31.00 | $1.85 | $2.11 | $1.56 |
| 2020 | $3.42 | $26.11 | $1.79 | $1.94 | $0.00 |
| 2021 | $2.69 | $25.96 | $1.58 | $1.64 | $0.00 |
| 2022 | $2.20 | $24.11 | $1.43 | $0.52 | $0.00 |
| 2023 | $2.03 | $39.57 | $0.97 | $0.00 | $0.00 |
| 2024 | $6.37 | $125.07 | $0.79 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cumberland Pharmaceuticals Inc.'s (CPIX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $125.07
- Current price
- $4.36
- AI upside
- +2,768.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.00
-31.19% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CPIX | Cumberland Pharmaceutical… | $4.36 | 73.59M | +2,769% | -31% | — | — | -13.82 | 3.92 | 2.37 | 505.27 | -304.09 | 22.58 | 82.61% | -16.99% | -17.11% | -24.71% | -23.24% | -8.24% | 0.90 | -10.62 | 1.15 | 0.94 | 14.30 | 455.00% | -426.00% | -11404.00% | -0.88% | -0.02 | -2.87% | 0.00% | 0.00% | 0.65% | -14.33 | -116.39 | 2.43 | 0.87 |
| ABVC | ABVC BioPharma, Inc. | $1.31 | 18.98M | +6,706% | +707,778% | — | — | -1.42 | 6.08 | 14.64 | -2.24 | — | 6.08 | 99.85% | -923.34% | -962.12% | -378.31% | -131.15% | -68.64% | 2.61 | -5.70 | 0.33 | 0.32 | -0.54 | -7667.00% | 23431.00% | -5701.00% | -24.25% | -0.28 | -51.48% | 0.00% | 0.00% | 0.10% | -2.07 | -5.38 | 19.10 | -14.83 |
| CALC | CalciMedica, Inc. | $0.52 | 7.44M | — | — | — | — | -1.84 | 1.75 | — | -0.27 | — | 1.75 | 0.00% | — | — | -121.42% | 659.51% | -85.68% | 0.00 | — | 5.34 | 5.07 | 0.33 | -8405.00% | — | -1803.00% | -83.97% | -5.74 | 576.40% | 0.00% | 0.00% | 9.55% | -0.27 | -0.31 | — | -11.56 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| DYAI | Dyadic International, Inc… | $0.78 | 28.19M | +4,253% | -26% | — | — | -7.32 | 17.21 | 12.16 | -7.12 | — | 17.21 | 65.82% | -168.82% | -166.19% | -139.16% | 396.74% | -64.01% | 2.05 | -13.79 | 4.01 | 3.88 | 0.27 | -1667.00% | 2058.00% | -4091.00% | -9.35% | -1.62 | 267.25% | 0.00% | 0.00% | 0.00% | -6.49 | -9.64 | 10.96 | -9.43 |
| LTRN | Lantern Pharma Inc. | $2.82 | 31.54M | — | — | — | — | -1.90 | 1.86 | — | -0.70 | 0.00 | 1.86 | 0.00% | — | — | -66.93% | 1620.51% | -60.04% | 0.01 | — | 5.83 | 5.54 | 0.33 | 13125510.00% | — | 2409.00% | -45.25% | -4.11 | 1300.25% | 0.00% | 0.00% | 0.00% | -0.70 | -0.88 | — | -0.66 |
| LVTX | LAVA Therapeutics N.V. | $1.74 | 45.77M | +2,166% | +1,689% | — | — | -1.54 | 1.39 | 3.22 | 1.39 | — | 1.39 | 100.00% | -247.81% | -209.60% | -63.64% | 72.75% | -27.52% | 0.19 | -57.66 | 4.40 | 4.25 | 1.27 | -4013.00% | 7701.00% | -5229.00% | -50.64% | -1.09 | 47.94% | 0.00% | 0.00% | 0.00% | 1.10 | 1.67 | -2.73 | -2.75 |
| NOTV | Inotiv, Inc. | $0.27 | 9.31M | +5,205% | +18% | — | — | -0.38 | 0.19 | 0.05 | 20.53 | — | -0.13 | 12.68% | -6.02% | -13.38% | -44.78% | -3.99% | -8.84% | 3.70 | -0.55 | 0.35 | 0.21 | 19.47 | -4964.00% | 454.00% | -702.00% | -102.98% | -0.02 | -4.47% | 0.00% | 0.00% | 0.00% | -16.44 | -18.77 | 0.99 | -1.15 |
| QNTM | Quantum BioPharma Ltd. | $3.55 | 13.64M | — | — | — | — | -0.35 | 0.46 | — | 0.08 | — | 0.80 | 0.00% | — | — | -120.69% | -212.74% | -86.23% | 0.07 | -339.16 | 1.80 | 1.65 | 0.36 | -5750.00% | — | -3649.00% | -130.92% | -1.03 | -90.66% | 0.00% | 0.00% | 52.41% | 0.07 | 0.16 | — | -16.34 |
| RMTI | Rockwell Medical, Inc. | $0.90 | 35.49M | +8,164% | -8% | +5% | — | -104.82 | 1.54 | 0.50 | 14.30 | — | 2.34 | 17.23% | 0.60% | -0.47% | -1.78% | 2.52% | -0.86% | 0.42 | 0.48 | 2.63 | 2.12 | -0.72 | -9300.00% | 2138.00% | -13291.00% | 6.34% | 0.30 | 13.21% | 0.00% | 0.00% | 13.08% | 69.49 | 13.24 | 0.42 | -6.06 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
- CEO
- A. J. Kazimi
- Employees
- 91
- Beta
- -0.53
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.00 ÷ $4.36) − 1 = -31.19% (DCF, example).